Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study

BACKGROUND: Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features’ value in predicting the TMB status of BLCA patients. METHODS: Totally, 75 patients with BLCA were enrolled. Radiomic features extracted f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xin, Qian, Wen-lei, Yan, Wei-feng, Pang, Tong, Gong, You-ling, Yang, Zhi-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285848/
https://www.ncbi.nlm.nih.gov/pubmed/34271855
http://dx.doi.org/10.1186/s12885-021-08569-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285848/
https://www.ncbi.nlm.nih.gov/pubmed/34271855
http://dx.doi.org/10.1186/s12885-021-08569-y

Ejemplares similares